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Abstract
Cerebellar granule cells precursors are derived from the upper rhombic lip and migrate tangentially independent of
glia along the subpial stream pathway to form the external germinal zone. Postnatally, granule cells migrate from
the external germinal zone radially through the Purkinje cell layer, guided by Bergmann glia fibers, to the internal
granular cell layer.
Medulloblastomas (MBs) are the most common malignant childhood brain tumor. Many of these tumors develop
from precursor cells of the embryonic rhombic lips. Four main groups of MB are recognized. The WNT group of
MBs arise primarily from the lower rhombic lip and embryonic brainstem. The SHH group of MBs originate from
cerebellar granule cell precursors in the external germinal zone of the embryonic cerebellum. The cellular origins of
type 3 and type 4 MBs are not clear.
Several ubiquitin ligases are revealed to be significant factors in development of the cerebellum as well as in the
initiation and maintenance of MBs. Proteasome dysfunction at a critical stage of development may be a major
factor in determining whether progenitor cells which are destined to become granule cells differentiate normally or
become MB cells. We propose the hypothesis that proteasomal activity is essential to regulate the critical transition
between proliferating granule cells and differentiated granule cells and that proteasome dysfunction may lead to
MB. Proteasome dysfunction could also account for various mutations in MBs resulting from deficiencies in DNA
checkpoint and repair mechanisms prior to development of MBs.
Data showing a role for the ubiquitin ligases β-TrCP, FBW7, Huwe1, and SKP2 in MBs suggest the possibility of a
classification of MBs based on the expression (over expression or under expression) of specific ubiquitin ligases
which function as oncogenes, tumor suppressors or cell cycle regulators.
Keywords: Cerebellar granule cells, Sonic hedgehog, WNT1, SCF-β-TrCP, E3 ligase F-box/WD repeat-containing
protein 7, E3 ligase S-phase kinase-associated protein 2
Introduction
Cerebellar neurons can be classified into inhibitory
gamma-butyric acid (GABAergic) and excitatory gluta-
matergic neurons [1]. The cerebellar GABAergic neurons
including Purkinje cells, and inhibitory interneurons,
Golgi cell, basket and stellate cells, are found in the cortex
[2–4]. Glutamatergic neurons include the granule cells,
unipolar brush cells, and large projection neurons in the
cerebellar nuclei [4–8]. The cerebellar granule cells are
the smallest and most abundant neurons in the vertebrate
brain [4, 9].
Cerebellar neurogenesis begins at around E8-E13/14
from cerebellar germinal zones that can be categorized
in four zones: 1. The internal germinal zone (ventricular
zone), 2. The external germinal zone (external granular
layer), 3. Upper rhombic lip (caudomedial germinal
zone) and 4. The rostral germinal zone (mesencephalon).
In this review we will discuss development of the rhom-
bic lip and the external germinal zone, the source of
granule cells, as they relate to the major types of medul-
loblastomas (MBs). Herein we also relate normal cere-
bellar development to signal transduction factors, and
discuss ubiquitin-proteasome dysfunction during devel-
opment as a major factor in development of MBs.
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Granule cell formation and cerebellar germinal zone
The rhombic lip is a highly proliferative region of the
neural fold located in rhombencephalon (r) that can be
divided into upper rhombic lip (r1) and lower rhombic
lip (r2-r8) [9, 10].
The upper rhombic lip or caudomedial germinal zone
of r1 is the main source of granule cell precursors which
are located at the interface of the ventricular zone and
the roof plate [4]. Granule cells precursors are created in
the caudomedial germinal zone from E12.5 to E17 and
they migrate rostrally in a subpial stream of cerebellar
primordium to establish the external germinal zone,
which is the location of non-committed granule cell pre-
cursors [10, 11].
The MATH1 gene, which encodes a bHLH transcrip-
tion factor, is expressed in the rhombic lip as well as in
proliferating granule cell precursors in the external ger-
minal zone. Targeted disruption of this gene results in
complete loss of the granule cell lineage [12, 13]. Math1
and Wntless (Wls) are expressed complementary in the
exterior and interior face of the rhombic lip [10]. Barhl1 is
a mouse homeobox gene that plays a role in cerebellum
development. It is activated by the transcription factor
MATH1, possibly in response to the growth factor BMP.
In glutamatergic neurons, the developmental protein
PAX6 is downstream in the MATH1 pathway [10], which
includes sequential expression of TBR2, NeuroD, and
TBR1 [14, 15].
Wnt1 is a glycoprotein that is important in maintain-
ing the isthmus organizer at the junction of mesenceph-
alon and rhombencephalon [16]. WNT1 is also
expressed at the caudal end of the caudomedial zone
[17]. Mutations in Wnt1 produce severe midbrain and
cerebellar defects [18]. However, the distribution and
molecular identity of WNT1 expressing progenitors have
not been carefully described in r1. Hagan and Zervas ob-
served that WNT1 lineage marked later in development
predominantly gave rise to granule cells in the adult
cerebellar cortex [17]. Lorenz et al. [19] reported that
Wnt/β-catenin signaling pathway is essential in prolifer-
ation and differentiation of cerebellar granule neuron
precursors. It is also been reported that lower rhombic
lip progenitors express WNT1 which give rise to neu-
rons of the precerebellar system, a major source of affer-
ent projections to the cerebellum [17].
The external germinal zone is a subpial location of
proliferating cerebellar granule cell precursors [4]. The
post-mitotic granule cells develop axons that extend
among the parallel fibers in the developing molecular
layer while the somata migrate inward to the granular
layer through the developing Purkinje cell layer (Fig. 1).
SHH-signaling has been shown to be an important
driver of granule cell progenitor proliferation [20, 21].
SHH secreted by Purkinje cells starting at around
embryonic day 18.5 in the mouse cerebellum [22]. Its re-
ceptor patched (PTCH1, alternatively referred to as
PTC1, PTC, or by the family name PTCH), a protein
that interacts with smoothened (SMO), and its effector,
GLI-2, exhibit similar temporal patterns of immunoreac-
tivity in the external germinal zone [22, 23].
The Bmi1 gene, which promotes cell proliferation, is
expressed strongly in the cells of the external germinal
zone at around E16.5 during mouse cerebellar develop-
ment. Bmi1 is expressed in parallel with N-MYC and
cyclin D2 in the external germinal zone of human cere-
bellum from 17 weeks gestation to 2 months postnatal
[24]. The Bmi1 gene is described as an oncogene [25]
which is transcribed as a transcription repressor which
inhibits the expression of the ubiquitin E3 ligase, Fbw7
[26]. BMI1 is also considered to have a critical role in
maintaining cyclin E (a substrate of Fbw7) [26].
Types of medulloblastomas
MBs are the most common malignant childhood brain
tumor. Some of these tumors develop from the progeni-
tor cells in the external germinal zone of the embryonic
cerebellum [27]. The cerebellar granule cell is the most
numerous neurons in the nervous system and is consid-
ered the likely source of a subgroup of MBs [28]. Clinic-
ally and molecularly four main types of MB are
recognized [29, 30]. These are described as the WNT
group, the SHH group and two other groups referred to
simply as groups 3 and 4. The relative percentages of the
various groups of MBs are approximately 11 % (Wnt),
28 % (SHH), 38 % (Group 3) and 34 % (Group 4) [31].
Subtypes of each of the main groups have been defined
based on genetic and molecular markers [32]. According
to the data of Schuller et al. [33], MBs of the SHH group
originate from cerebellar granule neuron precursors
(CGNP). However the cellular origins of group 3 and
group 4 MBs have not been definitively determined.
The WNT group of medulloblastomas
In the WNT group of MBs, there is overexpression of
genes associated with the WNT (Wingless-related inte-
gration site) signalling pathway, as well as overexpres-
sion of TGFβ [34]. Mutations of β-catenin are frequently
associated with this group. According to Kool et al. [34]
the TGFβ pathway may be activated in MB by β-catenin
mutations.
The WNT signalling pathways have been studied for
their role in embryonic development and in carcino-
genesis. β-catenin is the main mediator of the clas-
sical WNT pathway. It functions as a transcription
factor which ‘moonlights’ as a cell adhesion molecule [35].
β-catenin has a short half-life, which depends on
phosphorylation, ubiquitination and degradation by the
proteasome [36, 37]. Accumulation of unphosphorylated
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β-catenin facilitates translocation to the nucleus. To act as
a transcription factor in the nucleus β-catenin interacts
with LEF/TCF (Lymphoid enhancer factor/T cell factor
[38]. Disturbances of WNT/β-catenin signalling are con-
sidered to lead to defects in differentiation of mesenchy-
mal stem cells, developmental disorders and cancer [39].
Gibson et al. [40] reported a mouse model of WNT MB
with some evidence that the tumor arose primarily from
the lower rhombic lip and embryonic brainstem rather
than from the upper rhombic lip and cerebellum.
The SHH group of medulloblastomas
In the SHH signal transducing pathway when one of the
hedgehog family of proteins (Indian Hh, Sonic Hh, Des-
ert Hh) binds to the transmembrane receptor PTCH1,
another transmembrane protein smoothened (SMO) is
released to activate the GLI transcription factors. The
GLI factors in turn stimulate the expression of target
genes including oncogenes and tumor suppressor genes
[41]. Blockade of the SHH pathway is reported to inhibit
the growth of MB in culture [42].
Fig. 1 Timetable and sources of the cerebellar neurogenesis and granule cells formation: a-c Schematic illustration of the spatiotemporal
parameters at sagittal sections of the early cerebellar development (embryonic (e) day 10–13 (E10-E13) (a), E15-E17 (b), and postnatal (P) day 20
(P20) (c). Neuroepithelium of 4th ventricle (ventricular zone (vz)) is sources of all GABAergic neurons including Purkinje cells (green) under control
of NOTCH1 and PTF1a pathway. Rhombic lip (rl) under influence of BMP/LMX1a develop and is sources of all glutamatergic neurons including cerebellar
nuclei neurons (red) and external germinal zone (orange; source so granule cells). d-e Schematic illustration of the spatiotemporal
parameters in corticogensis and granule cells development Purkinje cells (green) express SHH that increases proliferative activity of
external germinal zone (EGZ) cells (precursor of granule cells). Reelin express from precursor of granule cells and causes dispersal of
Purkinje cells cluster (d) to monolayer (e-f). e Granule cells differentiate and migrate cross Purkinje cells layer to final destination i.e.
granular layer and granule cells development is completed by maturation in this layer. Abbreviations: Pcc = Purkinje cell clusters, Purkinje
cells precursor (pcp), mesencephalon (m), rhombic lip (rl) E = embryonic day, EGL (EGZ) = external germinal layer (zone), gc = granule cells,
m = mesencephalon, NTZ = nuclear transitory zone, A = Adult, pcl = Purkinje cell layer, rl = rhombic lip, ml = molecular layer
Vriend et al. Molecular Brain  (2015) 8:64 Page 3 of 14
In the SHH group of MBs there is overexpression of
genes for proteins in the SHH signaling pathway [34].
Thus expression of PTCH and GLI genes may be upreg-
ulated. Mutations of PTCH1, PTCH2, SMO, and SUFU
may occur in this group of MBs [43, 44]. Kool et al. [45]
have recently characterized the frequency of these muta-
tions at different ages. They found mutations of PTCH1
and SUFU were most frequent in infants; mutations of
PTCH1 and TP53 (tumor suppressor p53) most frequent
in young adults; mutations of PTCH1 and SMO in adults.
PTCH1 mutant mice are used as a model for MBs of the
SHH group. The SHH type of MBs in mouse models de-
velop from granule cell precursors of the cerebellum [33],
cells that normally differentiate into glutamatergic neu-
rons. It has however been noted that pediatric and adult
SHH MBs are molecularly distinct [43].
Group 3 tumors and MYC signaling
The group 3 MB tumors are sometimes referred to as
the MYC group since this transcription factor (which
also regulates histone acetylation) is overexpressed in
these tumors [29]. MYC (but not MYCN) amplification
according to Taylor et al. is mostly, but not exclusively,
limited to Group 3 tumors [29]. The cell surface recep-
tor, C-met (a kinase found in progenitor cells), and its
ligand HGF, apparently interact to stimulate MYC in this
group of tumors [46]. Immunocytochemically these tu-
mors are identified as positive for the NPR3 protein
(Natriuretic peptide receptor C) [43]. Tumors in this
group are also likely to overexpress genes for photorecep-
tor proteins, including S-antigen and opsin [29, 47]. In
humans there are often disruptions of the p53 signal-
ing pathway in these tumors [48]. Data in mice lack-
ing p53 in external germinal zone progenitor cells,
suggest that human Group 3 MB tumors appear to
originate from these progenitor cells [48]. Patients
with group 3 type tumors have the worst prognosis
[30]. A mouse model of MYC-driven MB has been
reported [49, 50]. In this model the cells of origin of
the MB was a granule cell precursor or a stem cell
not yet differentiated into granule cells.
Group 4 tumors
The group 4 MB tumors are often identified immunohis-
tochemically by the potassium channel marker KCNA1
[29], but less is known about the molecular characteristics
of this group than of the other groups.
Recently an attempt has been made to classify MBs on
the pattern of G-protein coupled receptor (GPCR) ex-
pression [51]. On this basis, Whittier and colleagues [51]
distinguished 5 groups of MBs. A cluster of tumors in
which the GPCR LGR5 (a stem cell marker) and GPR64
(an orphan receptor) is overexpressed corresponded to
the WNT group of MBs, whereas a cluster of tumors in
which the GPCR PTGER4 (a prostaglandin receptor) is
overexpressed corresponded to the SHH group of MBs.
The GPCR gene for melatonin (MTNR1A) was under
expressed in the histopathological Groups 3 and 4, as
well as the adenosine receptor, ADORA1. Four GPCRs
were overexpressed in all MB groups compared to con-
trol tissues. Other investigators have reported overex-
pression of somatostatin receptors, SSR2, in MBs [52]. A
recent report [53] provides evidence that the G protein
subunit Gαs is a tumor suppressor in the SHH MBs. G
protein subunit Gαs is found in granule cell precursors.
Silencing of the gene for this protein was reported as
sufficient to cause MB in mice.
Thus despite the heterogeneous nature of MBs, they
can be classified histopathologically as well as by GPCR
expression. Since GPCR signaling is regulated by the
ubiquitin proteasome system [54] this suggests a role for
the ubiquitin–proteasome system in classification of
MBs as well. While accurate classification of MBs is es-
sential to treatment, the heterogeneity of MBs makes
treatment a challenge.
The ubiquitin proteasome system and
medulloblastoma
The ubiquitin–proteasome system
The ubiquitin-proteasome system (UPS) has been de-
scribed in many reviews (e.g., [55, 56]). Ubiquitin is
added to proteins via a series of 3 enzymes, an activating
enzyme, E1, a conjugating enzyme, E2, and an ubiquitin
ligase, E3. Ubiquitination of proteins, among other func-
tions, facilitates degradation of proteins by the prote-
asome. The proteasome is composed of two subunits, a
19S regulatory particle and a 20S core particle contain-
ing degradative enzymes. The molecular structure of the
proteasome has been described in detail (e.g., [57, 58]).
Nahreini et al. [59] suggested that normal proteasome
activity is essential during neuronal cell differentiation. If
the ubiquitin proteasome system does not function ap-
propriately during differentiation by controlling degrad-
ation of signaling and transcription factors, the normal
fate of the cell will be altered. Thus, structural or func-
tional defects in ubiquitin ligases or in components of
the proteasome itself could alter the fate of the cell.
Several genes encoding signal transduction proteins
involved in development of the cerebellum may be dys-
regulated or mutated in MB. These proteins include the
transcription factors, β-catenin and GLI, as well as
cMYC and NOTCH. All four of these proteins are
regulated by SCF (An E3 ligase complex) mediated
degradation by the ubiquitin-proteasome system [60].
β-catenin and GLI3 are ubiquitinated by SCF-B-TrCP,
while cMYC is ubiquitinated by SCF-Fbw7 and SCF-
SKP2, and NOTCH is ubiquitinated by SCF-Fbw7
(Table 1). Mutation of the β -TrCP recognition site
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on the gene for β-catenin, CTNNB1, has been re-
ported to be associated with WNT tumors [61]. Mu-
tations of the APC (adenomatous polyposis coli) gene
are also found in some MBs [61]. APC is part of the
β -TrCP ligase complex that ubiquitinates β-catenin
prior to degradation by the proteasome. This is illus-
trated by Narayan and Roy [62] as it relates to colo-
rectal cancer. While to the best of our knowledge no
Table 1 Major substrates of SCF ubiquitin ligases, Fbw7, β-TrCP, and SKP2
SCF-Fbw7
Notch Cell proliferation signaling [140–143]
c-Myc Transcription factor [140, 144, 145]
c-Jun Kinase [146]
Cyclin E Cell cycle regulator [26, 147]
Mcl-1 Differentiation protein [148]
SREBP Transcription factor [149]
PGC-1a Transcription factor involved in energy metabolism [150]
Nrf-1 Transcription factor [151]
TGIF Transcriptional repressor of TGF-b [152]
Aurora-A Kinase and regulator of chromosome segregation [153, 154]
SV40 T antigen Viral oncogene [155]
KLF5 Transcription factor [156]
mTor Kinase [157]
SCF-βTrCP
Gli2 Transcription factor [158, 159]
GLi3 Transcription factor and mediator of SHH signaling [160, 161]
B-catenin Transcription factor and cell adhesion; mediator of Wnt signaling [162–164]
IkBα NFkB inhibitor [163–166]
mdm2 Ubiquitin ligase for p53 [148]
Wee1 Cell cycle regulator kinase
Cdc25a Phosphatase in cell cycle regulation [167]
Rest Gene suppressor and chromosome stabilizer [133]
Nrf-2 Transcription factor for antioxidant enzymes [168]
Emi1 Cell cycle regulator kinase [167]
HIV-1 Vpu Viral pseudosubstrate [169]
Per1/2 Circadian regulation [170–172]
Snail Neural crest regulation [173]
DEPTOR Autophagy inhibitor [174]
Mcl-1 Differentiation protein [175]
SCF-SKP2
p27 Cell cycle regulator [176, 177]
p21 Cell cycle regulator [178, 179]
E2F Transcription factor [180]
Akt Protein kinase [181]
FOX01 Transcription factor [182]
Brca2 DNA repair [183]
cyclin A Cell cycle regulator [184]
cyclin E Cell cycle regulator [185]
c-myc Transcription factor [186]
HPV Viral E7 Viral oncogene [187]
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mutations of SKP2 in MBs have been reported, it
should be noted that mutations of the β -TrCP com-
plex would interfere with SKP2 degradation [63].
While mutations of Fbw7 have apparently not been
reported in MBs, they have been well studied in T
cell acute lymphocytic leukemia. In this disease
cMYC, NOTCH and cyclin E tend to accumulate with
Fbw7 deficiency, along with inactivation of p53 [64].
The cycle protein p27 is regulated by SCF-Skp2. Skp2
control of p27 may be particularly important in the SHH
group of MBs [65]. The protein PTCH1, a receptor for
SHH, is also regulated by the ubiquitin-proteasome sys-
tem [66]. The HECT E3 ligase, Smurf regulates the deg-
radation of PTCH1 [67]. The ubiquitin E3 ligase for the
transmembrane protein, smoothened (SMO), is unknown.
The transcription factor MATH1 (ATOH1) is an im-
portant signaling factor in development of the cerebel-
lum [10]. MATH1 positive cells in the rhombic lip of
the developing cerebellum give rise to glutamatergic
cells. MATH1 is protected from degradation by the
ubiquitin-proteasome system by SHH signaling in gran-
ule cell progenitor of the external germinal zone [68].
According to these investigators the regulation of
MATH1 is an important factor controlling the switch
between proliferation and differentiation. The ubiquitin
HECT E3 ligase, Huwe1, regulates the stability of
MATH1. Disruption of SHH-MATH1 regulation may be
a factor in the development of SHH MBs. Forget and
colleagues [68] found if MATH1 was overexpressed, dif-
ferentiation of granule cells was inhibited, and migration
was impaired. They concluded that Huwe1-dependent
degradation of Math1 by the proteasome was required
for normal differentiation of granule neuron progenitor
cells. They also found that BMP inhibited MATH1 ex-
pression by a posttranslational mechanism. Their work
showed the importance of the ubiquitin-proteasome sys-
tem in controlling levels of the transcription factor
MATH1 in cerebellar granule cell progenitors. These in-
vestigators found that Huwe1 levels were decreased in
mouse SHH MBs. In human SHH MBs low HUWE1
levels were associated with poor prognosis [68] HUWE1
may regulate the stability of other proteins, including
the tumor suppressor p53 [69].
The tumor suppressor, SUFU (suppressor of fused), in-
hibits both the WNT and SHH pathways by promoting
the nuclear export of β-catenin and GLI [70], an SHH
stimulated transcription factor. Degradation of SUFU by
the ubiquitin-proteasome system is stimulated by SHH
[71]. SUFU interacts with GLI, to control cerebellar
morphogenesis [72]. In Xenopus embryos SUFU is re-
ported as a regulator of both WNT and SHH pathways
[73] during neural induction and patterning. To the
extent that SUFU regulates transcription factors in
granule cells dysregulation of this protein has been
suggested as contributing to the development of MB
[70]. Mutations of SUFU have been reported in young
children with MB [74].
In culture bone morphogenic proteins (BMP2 and
BMP4) inhibit proliferation and induce differentiation
of cerebellar granule neuron progenitors and MB
cells. Genes regulating the BMPs are decreased in ex-
pression in mouse MBs [75]. Zhao et al. [75] reported
that BMPs could be clinically useful inhibitors of
MBs. The ubiquitin ligase Smurf1 is a major regulator
of BMP signaling [76].
The two SCF ubiquitin ligases Fbw7 and β-TrCP have
been studied for their roles in tumorigenesis. Lau and
colleagues [77] reviewed the literature on how the
ubiquitin-proteasome processing of substrates of these
ligases promoted carcinogenesis. The Fbw7 gene, which
encodes Fbw7, regulates a number of proteins important
in tumorigenesis including c-JUN, NOTCH, cyclin E,
SREBP1, mTOR, c-MYC, MCL-1, NRF-1 and the proto-
oncogene DEK [78, 79]. According to Wang and col-
leagues [80] the E3 ligase Fbw7 is as a tumor suppressor
in a variety of cancers. Davis and colleagues [79] sug-
gested that Fbw7-associated tumorigenesis requires the
dysregulation of multiple oncoproteins. Fbw7 has been
reported to cooperate with β-TrCP in the ubiquitin-
proteasomal degradation of the myeloid cell leukemia
factor (Mcl-1) [81]. NRF1 in the nucleus is degraded by
β-TrCP and Fbw7 and in the ER- associated pathway by
the ligase Hrd1 [82].
Loss of Fbw7 may result in various types of cancer
[79]. Indeed, it has been described as a ‘bona fida tumor
suppressor’ [77]. Decreased Fbw7 would be expected to
be of particular importance in MBs with MYC overex-
pression since it is the ubiquitin ligase for this protein.
Rajagopalan and colleagues [83] implicated cyclin E as a
possible mediator of Fbw7 mediated tumor initiation
through its stimulation of genetic instability. Mao and
colleagues [26] noted that the transcription repressor,
Bmi1 stabilizes cyclin E levels in the cell by inhibiting
transcription of Fbw7. It would be expected to stabilize
other substrates of Fbw7 (Table 1) as well. Fbw7 is re-
ported as decreased in some cases of MB [84].
The ubiquitin ligase β-TrCP might be expected to be of
more significance in the WNT group of MBs via its pro-
teolytic control of β-catenin. β-TrCP could also be of im-
portance in the SHH group of MBs via its ubiquitination
of the GLI3 protein [85]. It is also a ubiquitin ligase for
MDM2, a regulator of the tumor suppressor p53 [77]. Fur-
thermore, B-TrCP is a ligase for Emi1, an inhibitor of the
Anaphase Promoting Complex (APC/C) [86]. APC/C, a
tumor suppressor, itself is a ubiquitin ligase for casein
kinase1δ in cerebellar granule precursor cells [87].
Hede et al., reported increased expression of the β-
TrCP and SKP2 ubiquitin ligases in some MBs [84].
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Overexpression of the ubiquitin ligase SKP2 is reported
in various tumors and has been suggested to be of im-
portance in the SHH group of tumors [65].
Dysregulation of ubiquitin ligases appears to be a com-
ponent of at least some types of MB. It would be useful
to have information on expression of Fbw7, SKP2, and
β-TrCP in the 4 different classification types of MB.
These three ubiquitin ligases have been most extensively
studied for their role in initiation and maintenance of
tumors [79]. They appear to be of critical significance as
epigenetic factors controlling the balance of expression
of oncogenes and tumor suppressive proteins (Fig. 2).
They are also the three main F-box ligases (of over 70
identified) known to regulate the cell cycle [88].
The ubiquitin-proteasome system and NF-κB in
medulloblastoma
High levels of NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) activity has been reported
in MB cell lines and in MB xenograft tumors [89]. A
number of drugs that inhibit NF-κB activity in cell lines
inhibited tumor growth as well [89]. According to
Northcott et al. [90] NF-κB signaling is particularly pre-
dominant in Group 4 MBs. The ubiquitin ligase β-TrCP
regulates the degradation of the NF-κB inhibitor IkBα
[91]. Proteasome inhibitors such as bortezomib are well
known for their ability to inhibit NF-κB [92].
The proteasome and DNA repair
Mutations in various genes, including those for SUFU,
SMO, PTCH, MycN [45, 93], β-catenin [61], APC [94]
and TP53 [95], have been reported as causal factors in
MB. Mutations associated with MB suggest the possibil-
ity that DNA repair mechanisms have been compro-
mised. One mechanism suggested as contributing to MB
development is that of a defect in DNA repair mecha-
nisms in progenitor cells [96]. Lee and colleagues [97]
and Frappart et al. [98] have reported MBs arising from
DNA repair deficiencies in conjunction with p53 dys-
function and genome rearrangement. One of the major
functions of the ubiquitin-proteasome system is that of
regulation of DNA repair [99]. Thus dysfunction of the
ubiquitin-proteasome system could contribute to com-
promised DNA repair mechanisms leading to MBs.
Proteasome inhibitors and medulloblastoma
A variety of signal transduction factors have been impli-
cated in the differentiation and proliferation of MB cells
(Table 1). Ubiquitination of these proteins is necessary
for processing prior to degradation, or for functioning as
Fig. 2 The SCF ligases, Fbw7, SKP2, and β-TrCP regulate oncogenes and tumor suppressors in medulloblastomas: Schematic illustration of the cell
summarizes the important SCF ligases, Fbw7, SKP2, and β-TrCP and important substrate that after ubiquitination targeted by proteasom for
degradation. Fbw7 - ubiquitin ligase F-box WD repeat containing protein 7; Skp2 - ubiquitin ligase S-phase kinase associated protein; Β-TrCP -
ubiquitin ligase B-transducin repeats-containing protein. Ubiquitin, Sub; substrate, tf; transcription factor
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a transcription factor. Proteasome inhibitors thus influ-
ence both gene transcription and protein degradation.
The proteasome inhibitor bortezomib, approved by the
FDA for treatment of multiple myeloma and mantle cell
lymphoma, has been used in preclinical studies to inhibit
CNS tumor growth [100]. Bortezomib was reported to
inhibit the growth of neuroblastoma cells injected into
mice [100]. The signal transducing factor, TRAIL, en-
hanced the sensitivity of these tumors to the proteasome
inhibitor [100]. Bortezomib induces apoptosis of human
medulloblastoma cells and inhibits AKT and NF-κB sig-
naling [101]. It also induces apoptosis in vivo in a mouse
model of the SHH type of medulloblastoma [102]. In an-
other mouse model of MB, in which PTCH1 is inacti-
vated, bortezomib had anti-tumor activity, down-
regulated the SHH pathway and restored PTCH1 levels
[103]. Based on in vitro studies and on mouse xenograft
models Yang et al. suggested the use of bortezomib in
treatment of pediatric MBs [101]. However pharmaco-
logical studies have shown that bortezomib does not
readily cross the blood–brain barrier [104]. It could
however be tested in those MBs that during growth dis-
rupt the blood brain barrier. The need for developing
proteasome inhibitors that do cross the blood–brain bar-
rier is warranted. Bortezomib can stabilize β-catenin in
mesenchymal stem cells and influence their differenti-
ation [105]. Luchetti et al. [106] suggested that at least
one signaling pathway may acts as a molecular switch in
differentiation of stem cells into neural progenitor cells.
The ubiquitin ligase Smurf2 has been reported to en-
hance neuron differentiation from mesenchymal stem
cells [107]. A previous review summarized the role of
the ubiquitin proteasome system in differentiation of
stem cells and progenitor cells [108] The role of prote-
asome inhibitors such as bortezomib on differentiation
suggests that the UPS may have a critical role regulating
the differentiation of neural progenitor cells which give
rise to granule cells during the critical period when they
are susceptible to being transformed into MB cells. Re-
cent evidence indicates that the ubiquitin ligase APC/C
contributes to regulation of cerebellar granule cell pro-
genitor cells [87].
Proteasome and apoptosis in granule cells
The proteasome has some paradoxical effects on apop-
tosis. The ubiquitin-proteasome system regulates several
proteins related to apoptosis. In HL60 leukemia cells
proteasome inhibitors activate apoptosis [109]. In cells
such as sympathetic neurons, however, proteasome in-
hibitors may be pro-apoptotic [110]. Canu et al. reported
anti-apoptotic effects in cerebellar granule cells from
8 day old rats [111]. Thus the proteasome inhibitors, lac-
tacystin and MG132, were found to protect granule cells
from apoptosis induced by decreasing extracellular
potassium, if administered at the beginning of apoptosis
[111]. In addition, Canu et al. [111] noted that ubiquiti-
nated proteins accumulated in dying cells undergoing
apoptosis. These findings lead Canu et al. to conclude
that the cerebellar granule cell was a useful model for
studying the relationship of the proteasome to pro-
grammed cell death [111]. Other investigators have
noted that anti-apoptotic factors, such as Bcl-2, are over-
expressed in a substantial percentage of desmoplastic
MBs (SHH group) [112]. The SHH type of MB is
thought to originate from cells in the external germinal
layer of the cerebellum [113]. Bcl-2 expression in early
differentiating granule cells (from 5 day old rats) is re-
ported to be required for the anti-apoptotic action of the
thyroid hormone, T3 [114] and cell survival. Bcl-2 is
considered to play a role in regulating developmental
cell death in embryonic precursor cells [114, 115]. It ap-
pears to be well expressed in undifferentiated granule
cell precursors [112]. It should be noted that the protein
complex Keap1 Cul3-Rbx1 is reported to be the ubiqui-
tin ligase for Bcl-2 [116, 117]. It is also a sensor for oxi-
dative stress [118] and is thought to act as a tumor
suppressor [116].
Bobba et al. [119] reported that proteasome inhibitors
prevent cytochrome C release during apoptosis in cere-
bellar granule neurons of 7 day old rats. They reasoned
that the proteasome was required to initiate the process
of apoptosis and concluded that proteasome inhibitors
rescued cells from apoptosis. However, Porcile et al.
[120] also using cerebellar granule neurons of 7 day old
rats reported that proteasome inhibitors induce cerebel-
lar granule cell death. These conflicting results were
somewhat clarified by the results of Butts et al. [121].
They reported a biphasic effect of proteasome inhibition
in 7–8 day rat cerebellar granule cells. Short term prote-
asome inhibition protected cells from apoptosis whereas
long term inhibition was pro-apoptotic and possibly
toxic [119]. Acute exposure of granule cells to prote-
asome inhibition increased levels of the pro-survival fac-
tor, MEF2D. Chronic exposure of granule cells to
proteasome inhibition was found to increase levels of c-
JUN and of the pro-apoptotic factor Bim.
It should be noted that the proteasome contributes to
the degradation of anti-apoptotic proteins including Bcl-
2 and IAP [122] as well as pro-apoptotic proteins includ-
ing BAX [123]. The time of exposure and dose of prote-
asome inhibitors used can be factors in determining
whether a proteasome inhibitor is pro-apoptotic or pro-
survival [121, 124]. In cancer cells proteasome inhibitors
tend to be pro-apoptotic [125].
Proteasome activity, however, is essential for proliferat-
ing cells. NF-κB reportedly contributes to the survival of
cerebellar granule cells [126]. Its degradation is regulated
by the ubiquitin-proteasome system.
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The proteasome and differentiation
Nahreini et al. [59] have studied the role of the prote-
asome in differentiation of mouse neuroblastoma cells.
In the NBP2 cell line elevation of intracellular cAMP
stimulates differentiation of these neurons. Their data
showed that N-MYC and cyclin B1 transcription (and
translation into protein) were decreased by cAMP-
inducing agents during differentiation to the mature cell
type. The proteasome inhibitor, lactacystin, also de-
creased N-MYC and cyclin B1 transcription into mRNA
but increased the cellular concentrations of these differ-
entiation proteins and led to cell death. They concluded
that the proteasome was essential for differentiation and
that the NBP2 cell model would be useful for testing a
combination of cAMP induced differentiation in com-
bination with proteasome inhibition as a treatment for
neuroblastoma.
N-MYC regulates the cell cycle in cerebellar granule
cell precursors [127]. SHH proliferative activity requires
N-MYC expression. It is blocked by bone morphogenetic
protein 2, BMP2 [128]. According to Alvarez-Rodriguez
et al. [128], BMP2 promotes differentiation of cerebellar
granule cell precursors. It should be noted that the ubi-
quitin ligase for N-MYC is HUWE1 [127].
REST, MAD and cell cycle control
It has been reported that abnormal expression of the re-
pressor element silencing transcription factor (REST) is
one cause for MBs [129–131]. The fact that a number of
MBs overexpress this factor supports this interpretation
[132]. Negrini et al. [131] describe REST as an oncogene
in MBs and neuroblastomas. Westbrook et al. [133] re-
ported that the E3 ligase that regulates REST ubiquitina-
tion and degradation is β-TrCP. These investigators
found that REST over-expression caused oncogenic
transformation of human mammary epithelial cells. Fres-
cas and Pagano [134] noted that REST overexpression
can not only inhibit differentiation but also cause
chromosomal instability, both of which can contribute
to development of tumors.
Another protein expressed in the external germinal
zone is the MAD3 protein, a member of a family of tran-
scriptional regulators, to which MYC also belongs. This
protein is reported to be an important regulator of gran-
ule cell precursors [135]. Both MAD2 and MAD3 are
components of the spindle checkpoint of the cell cycle
and inhibitors of the APC/C (anaphase-promoting com-
plex) ubiquitin ligase [136]. APC/C in turn is regulated
by β-TrCP, through degradation of the APC/C inhibitor
EMI1 (early mitotic inhibitor) [86]. β-TrCP, as noted
above, is also a ligase for REST, and an inhibitor of
MAD expression during the spindle checkpoint of the
cell cycle [137] and securin, another spindle checkpoint
protein [138]. Guardavaccaro and colleagues [137]
pointed out that prevention of REST degradation by β
-TrCP may contribute to tumor formation by causing
genomic instability.
Perspectives of proteasome therapy in medulloblastoma
It has been suggested that proteasome inhibitors have
potential as therapeutic agents in treating MBs [101]. As
noted above a problem using some proteasome inhibi-
tors to treat MBs is that the blood brain barrier limits
the use of those that cannot cross it. Another major
problem using proteasome inhibitors to treat MBs is
their lack of specificity. Proteasome inhibitors may in-
hibit the degradation of both tumor suppressors and
oncoproteins [139]. Inhibitors of ligases, such as inhibi-
tors of the SKP2 ligase, would be more specific. Finally
deubiquitinase inhibitors could also be useful in counter-
acting excess degradation of tumor suppressor proteins.
Agents such as these need to be developed and tested
for their effectiveness in individuals of the four main
groups of MBs.
Conclusion
Hypothesis: Proteasomal activity is essential to regulate
the critical transition between proliferating granule cells
and differentiated granule cells. Proteasomal dysfunction
may be a major factor in determining whether progeni-
tor cells which are destined to become granule cells, dif-
ferentiate normally or instead become MB cells. Of
particular significance for the development of MBs are
the three SCF ligases, SKP2, FBW7, and β-TrCP, all of
which are intimately involved in cell cycle regulation.
Targeting SCF ligases may be effective in modulating
stem cells involved in initiation of MB tumor cells. Tar-
geting SCF ligases may also be significant for a variety of
neural and non-neural tumors in which these ligases
play a role in tumor initiation and in tumor cell
proliferation.
Highlights
 Several ubiquitin ligases important in development
of the cerebellum are also significant factors in the
development of medulloblastomas
 The ubiquitin ligase SCF-β-TrCP regulates degrad-
ation of several proteins in the Wnt and SHH group
of medulloblastomas including β-catenin, Gli2/3,
and mdm2
 SCF- β-TrCP, also regulates the inhibitor of NF-κB,
IkBα, the transcription repressor element REST, and
Emi1(an inhibitor of APC/C)
 The ubiquitin ligase SCF-Fbw7 which acts as a
tumor suppressor regulates degradation of proteins
of significance in type 3 medulloblastomas including
Myc, Notch, cyclin E
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 The ligase SCF-Skp2 which regulates the cell cycle
protein p21 and p27 is elevated in a population of
medulloblastomas
 The ubiquitin ligase, Huwe1, regulates degradation
of Math1, which regulates the balance between
proliferation and differentiation in granule neural
progenitor cells
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coupled receptor; IAP: Inhibitor of apoptosis; LEF/TCF: Lymphoid enhancer
factor/T cell factor; MAD: Mitotic arrest deficient; MATH1: Protein atonal
homolog 1 (alias ATOH1); MB: Medulloblastoma; MYC: Myelocytomatosis
oncogene; MCL -1: Myeloid leukemia cell differentiation protein; NF-κB: Nuclear
factor kappa-light-chain-enhancer of activated B cells); PTCH: Patched, a family
of membrane receptors including PTCH1 and PTCH2; REST: Repressor element
silencing transcription factor; SCF: Skp, Cullin, F-box complex; SCF- β -TrCP: E3
ligase β-transducin repeats-containing protein; SCF-Skp2: E3 ligase S-phase
kinase-associated protein 2; SCF-Fbw7: E3 ligase F-box/WD repeat-containing
protein 7; SHH: Sonic hedgehog; SMO: Smoothened; SUFU: Suppressor of fused
homolog; TRAIL: TNF-related apoptosis-inducing ligand; Wls: Wntless;
Wnt: Wingless-related integration site gene.
Competing interests
All authors have no competing interest for this review article which might
affect their interpretation of data or presentation of information.
Authors’ contributions
HM participated in preparation of the developmental part of the review; JV
wrote the sections relating to the UPS system; SG was involved in general
aspect of the manuscript preparation and JV, SG, and HM participated in
final proof reading of the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
JV is supported by the University of Manitoba professional development
funds. HM holds grants from the Natural Sciences and Engineering Research
Council of Canada (NSERC Discovery Grant 341921–2012) and a FHS Bridge
Funding of Highly Ranked CIHR Open Operating Grants.
Received: 18 May 2015 Accepted: 8 October 2015
References
1. Carletti B, Rossi F. Neurogenesis in the cerebellum. Neuroscientist.
2008;14(1):91–100. doi:10.1177/1073858407304629.
2. Castejon OJ. Ultrastructural alterations of human cortical capillary basement
membrane in human brain oedema. Folia Neuropathol. 2014;52(1):10–21.
3. Leto K, Rossi F. Specification and differentiation of cerebellar GABAergic
neurons. Cerebellum. 2012;11(2):434–5. doi:10.1007/s12311-011-0324-8.
4. Marzban H, Del Bigio MR, Alizadeh J, Ghavami S, Zachariah RM, Rastegar M.
Cellular commitment in the developing cerebellum. Front Cell Neurosci.
2014;8:450. doi:10.3389/fncel.2014.00450.
5. Cotterill RM. Cooperation of the basal ganglia, cerebellum, sensory
cerebrum and hippocampus: possible implications for cognition,
consciousness, intelligence and creativity. Prog Neurobiol. 2001;64(1):1–33.
6. Laine J, Axelrad H. The candelabrum cell: a new interneuron in the
cerebellar cortex. J Comp Neurol. 1994;339(2):159–73. doi:10.1002/
cne.903390202.
7. Sillitoe RV, Joyner AL. Morphology, molecular codes, and circuitry produce
the three-dimensional complexity of the cerebellum. Annu Rev Cell Dev
Biol. 2007;23:549–77. doi:10.1146/annurev.cellbio.23.090506.123237.
8. Voogd J, Glickstein M. The anatomy of the cerebellum. Trends Neurosci.
1998;21(9):370–5.
9. Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, et al.
Equal numbers of neuronal and nonneuronal cells make the human brain
an isometrically scaled-up primate brain. J Comp Neurol. 2009;513(5):532–41.
doi:10.1002/cne.21974.
10. Yeung J, Ha TJ, Swanson DJ, Choi K, Tong Y, Goldowitz D. Wls provides a
new compartmental view of the rhombic lip in mouse cerebellar
development. J Neurosci. 2014;34(37):12527–37. doi:10.1523/
JNEUROSCI.1330-14.2014.
11. Machold R, Fishell G. Math1 is expressed in temporally discrete pools of
cerebellar rhombic-lip neural progenitors. Neuron. 2005;48(1):17–24.
doi:10.1016/j.neuron.2005.08.028.
12. Wang VY, Zoghbi HY. Genetic regulation of cerebellar development. Nat
Rev Neurosci. 2001;2(7):484–91. doi:10.1038/35081558.
13. Fink AJ, Englund C, Daza RA, Pham D, Lau C, Nivison M, et al. Development
of the deep cerebellar nuclei: transcription factors and cell migration from
the rhombic lip. J Neurosci. 2006;26(11):3066–76. doi:10.1523/
JNEUROSCI.5203-05.2006.
14. Bulfone A, Martinez S, Marigo V, Campanella M, Basile A, Quaderi N, et al.
Expression pattern of the Tbr2 (Eomesodermin) gene during mouse and
chick brain development. Mech Dev. 1999;84(1–2):133–8.
15. Lee JK, Cho JH, Hwang WS, Lee YD, Reu DS, Suh-Kim H. Expression of
neuroD/BETA2 in mitotic and postmitotic neuronal cells during the
development of nervous system. Dev Dyn. 2000;217(4):361–7. doi:10.1002/
(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8.
16. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for
development of a large region of the mouse brain. Cell. 1990;62(6):1073–85.
17. Hagan N, Zervas M. Wnt1 expression temporally allocates upper rhombic lip
progenitors and defines their terminal cell fate in the cerebellum. Mol Cell
Neurosci. 2012;49(2):217–29. doi:10.1016/j.mcn.2011.11.008.
18. Thomas KR, Musci TS, Neumann PE, Capecchi MR. Swaying is a mutant
allele of the proto-oncogene Wnt-1. Cell. 1991;67(5):969–76.
19. Lorenz A, Deutschmann M, Ahlfeld J, Prix C, Koch A, Smits R, et al. Severe
alterations of cerebellar cortical development after constitutive activation of
Wnt signaling in granule neuron precursors. Mol Cell Biol. 2011;31(16):3326–38.
doi:10.1128/MCB.05718-11.
20. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in
the cerebellum by Sonic Hedgehog. Neuron. 1999;22(1):103–14.
21. Haldipur P, Bharti U, Govindan S, Sarkar C, Iyengar S, Gressens P, et al.
Expression of Sonic hedgehog during cell proliferation in the human
cerebellum. Stem Cells Dev. 2012;21(7):1059–68. doi:10.1089/scd.2011.0206.
22. Corrales JD, Rocco GL, Blaess S, Guo Q, Joyner AL. Spatial pattern of sonic
hedgehog signaling through Gli genes during cerebellum development.
Development. 2004;131(22):5581–90. doi:10.1242/dev.01438.
23. Haldipur P, Bharti U, Alberti C, Sarkar C, Gulati G, Iyengar S, et al. Preterm
delivery disrupts the developmental program of the cerebellum. PLoS One.
2011;6(8), e23449. doi:10.1371/journal.pone.0023449.
24. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, et al. Bmi1
is essential for cerebellar development and is overexpressed in human
medulloblastomas. Nature. 2004;428(6980):337–41. doi:10.1038/nature02385.
25. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, et al. BMI1 is a
target gene of E2F-1 and is strongly expressed in primary neuroblastomas.
Nucleic Acids Res. 2006;34(6):1745–54. doi:10.1093/nar/gkl119.
26. Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, et al. Cyclin E1 is a common
target of BMI1 and MYCN and a prognostic marker for neuroblastoma
progression. Oncogene. 2012;31(33):3785–95. doi:10.1038/onc.2011.536.
27. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet
Oncol. 2004;5(4):209–18. doi:10.1016/S1470-2045(04)01424-X.
28. Jensen P, Smeyne R, Goldowitz D. Analysis of cerebellar development in
math1 null embryos and chimeras. J Neurosci. 2004;24(9):2202–11.
doi:10.1523/JNEUROSCI.3427-03.2004.
29. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al.
Molecular subgroups of medulloblastoma: the current consensus. Acta
Neuropathol. 2012;123(4):465–72. doi:10.1007/s00401-011-0922-z.
30. Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, et al.
Cytogenetic prognostication within medulloblastoma subgroups. J Clin
Oncol. 2014;32(9):886–96. doi:10.1200/JCO.2013.50.9539.
31. DeSouza RM, Jones BR, Lowis SP, Kurian KM. Pediatric medulloblastoma -
update on molecular classification driving targeted therapies. Front Oncol.
2014;4:176. doi:10.3389/fonc.2014.00176.
32. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al.
Molecular subgroups of medulloblastoma: an international meta-analysis of
Vriend et al. Molecular Brain  (2015) 8:64 Page 10 of 14
transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3,
and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–84.
doi:10.1007/s00401-012-0958-8.
33. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of
granule neuron precursor identity is a critical determinant of progenitor cell
competence to form Shh-induced medulloblastoma. Cancer Cell.
2008;14(2):123–34. doi:10.1016/j.ccr.2008.07.005.
34. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated
genomics identifies five medulloblastoma subtypes with distinct genetic
profiles, pathway signatures and clinicopathological features. PLoS One.
2008;3(8), e3088. doi:10.1371/journal.pone.0003088.
35. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin
pathways. Science. 2004;303(5663):1483–7. doi:10.1126/science.1094291.
36. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu
Rev Cell Dev Biol. 1998;14:59–88. doi:10.1146/annurev.cellbio.14.1.59.
37. Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C. The emerging
role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
Leukemia. 2007;21(8):1638–47. doi:10.1038/sj.leu.2404732.
38. Couffinhal T, Dufourcq P, Duplaa C. Beta-catenin nuclear activation:
common pathway between Wnt and growth factor signaling in vascular
smooth muscle cell proliferation? Circ Res. 2006;99(12):1287–9. doi:10.1161/
01.RES.0000253139.82251.31.
39. Logan CY, Nusse R. The Wnt signaling pathway in development and
disease. Annu Rev Cell Dev Biol. 2004;20:781–810. doi:10.1146/
annurev.cellbio.20.010403.113126.
40. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al.
Subtypes of medulloblastoma have distinct developmental origins. Nature.
2010;468(7327):1095–9. doi:10.1038/nature09587.
41. Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic
target in pancreatic cancer. World J Gastroenterol. 2014;20(9):2335–42.
doi:10.3748/wjg.v20.i9.2335.
42. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol.
2008;26(17):2821–7. doi:10.1200/JCO.2007.15.2264.
43. Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, et al.
Pediatric and adult sonic hedgehog medulloblastomas are clinically and
molecularly distinct. Acta Neuropathol. 2011;122(2):231–40. doi:10.1007/
s00401-011-0846-7.
44. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. Lack of Rb and
p53 delays cerebellar development and predisposes to large cell anaplastic
medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res.
2006;66(10):5190–200. doi:10.1158/0008-5472.CAN-05-3545.
45. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, et al.
Genome sequencing of SHH medulloblastoma predicts genotype-related
response to smoothened inhibition. Cancer Cell. 2014;25(3):393–405.
doi:10.1016/j.ccr.2014.02.004.
46. Guessous F, Li Y, Abounader R. Signaling pathways in medulloblastoma.
J Cell Physiol. 2008;217(3):577–83. doi:10.1002/jcp.21542.
47. Gielen GH, Gessi M, Denkhaus D, Pietsch T. CRX/OTX3: a useful marker in
the differential diagnosis of tumors of the pineal region and indicator of
photoreceptor differentiation in medulloblastomas and atypical teratoid
rhabdoid tumors. Appl Immunohistochem Mol Morphol. 2013;21(3):248–53.
doi:10.1097/PAI.0b013e3182649dad.
48. Marino S. Medulloblastoma: developmental mechanisms out of control.
Trends Mol Med. 2005;11(1):17–22. doi:10.1016/j.molmed.2004.11.008.
49. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal
model of MYC-driven medulloblastoma. Cancer Cell. 2012;21(2):155–67.
doi:10.1016/j.ccr.2011.12.021.
50. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, et al. A mouse
model of the most aggressive subgroup of human medulloblastoma.
Cancer Cell. 2012;21(2):168–80. doi:10.1016/j.ccr.2011.12.023.
51. Whittier KL, Boese EA, Gibson-Corley KN, Kirby PA, Darbro BW, Qian Q, et al.
G-protein coupled receptor expression patterns delineate medulloblastoma
subgroups. Acta Neuropathol Commun. 2013;1(1):66. doi:10.1186/
2051-5960-1-66.
52. Fruhwald MC, O’Dorisio MS, Pietsch T, Reubi JC. High expression of
somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for
diagnosis and therapy. Pediatr Res. 1999;45(5 Pt 1):697–708. doi:10.1203/
00006450-199905010-00016.
53. He X, Zhang L, Chen Y, Remke M, Shih D, Lu F, et al. The G protein alpha
subunit Galphas is a tumor suppressor in Sonic hedgehog-driven
medulloblastoma. Nat Med. 2014;20(9):1035–42. doi:10.1038/nm.3666.
54. Alonso V, Friedman PA. Minireview: ubiquitination-regulated G protein-
coupled receptor signaling and trafficking. Mol Endocrinol. 2013;27(4):558–72.
doi:10.1210/me.2012-1404.
55. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic
pathway: destruction for the sake of construction. Physiol Rev.
2002;82(2):373–428. doi:10.1152/physrev.00027.2001.
56. Gallastegui N, Groll M. The 26S proteasome: assembly and function of a
destructive machine. Trends Biochem Sci. 2010;35(11):634–42. doi:10.1016/
j.tibs.2010.05.005.
57. Tomko Jr RJ, Hochstrasser M. Molecular architecture and assembly of the
eukaryotic proteasome. Annu Rev Biochem. 2013;82:415–45. doi:10.1146/
annurev-biochem-060410-150257.
58. Kunjappu MJ, Hochstrasser M. Assembly of the 20S proteasome. Biochim
Biophys Acta. 2014;1843(1):2–12. doi:10.1016/j.bbamcr.2013.03.008.
59. Nahreini P, Andreatta C, Prasad KN. Proteasome activity is critical for the
cAMP-induced differentiation of neuroblastoma cells. Cell Mol Neurobiol.
2001;21(5):509–21.
60. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta
Neuropathol. 2009;118(3):329–47. doi:10.1007/s00401-009-0560-x.
61. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas
contain oncogenic beta-catenin mutations. Cancer Res. 1998;58(5):896–9.
62. Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the
development of colorectal cancers. Mol Cancer. 2003;2:41. doi:10.1186/
1476-4598-2-41.
63. Wei S, Chu PC, Chuang HC, Hung WC, Kulp SK, Chen CS. Targeting the
oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel
energy restriction-mimetic agent. PLoS One. 2012;7(10), e47298. doi:10.1371/
journal.pone.0047298.
64. Crusio KM, King B, Reavie LB, Aifantis I. The ubiquitous nature of cancer: the
role of the SCF(Fbw7) complex in development and transformation.
Oncogene. 2010;29(35):4865–73. doi:10.1038/onc.2010.222.
65. Bhatia B, Malik A, Fernandez LA, Kenney AM. p27(Kip1), a double-edged
sword in Shh-mediated medulloblastoma: Tumor accelerator and
suppressor. Cell Cycle. 2010;9(21):4307–14.
66. Lu X, Liu S, Kornberg TB. The C-terminal tail of the Hedgehog receptor
Patched regulates both localization and turnover. Genes Dev.
2006;20(18):2539–51. doi:10.1101/gad.1461306.
67. Huang S, Zhang Z, Zhang C, Lv X, Zheng X, Chen Z, et al. Activation of
Smurf E3 ligase promoted by smoothened regulates hedgehog signaling
through targeting patched turnover. PLoS Biol. 2013;11(11), e1001721.
doi:10.1371/journal.pbio.1001721.
68. Forget A, Bihannic L, Cigna SM, Lefevre C, Remke M, Barnat M, et al. Shh
signaling protects Atoh1 from degradation mediated by the E3 ubiquitin
ligase Huwe1 in neural precursors. Dev Cell. 2014;29(6):649–61. doi:10.1016/
j.devcel.2014.05.014.
69. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical
mediator of the ARF tumor suppressor. Cell. 2005;121(7):1071–83.
doi:10.1016/j.cell.2005.03.037.
70. Scotting PJ, Walker DA, Perilongo G. Childhood solid tumours: a
developmental disorder. Nat Rev Cancer. 2005;5(6):481–8. doi:10.1038/nrc1633.
71. Yue S, Chen Y, Cheng SY. Hedgehog signaling promotes the degradation of
tumor suppressor Sufu through the ubiquitin-proteasome pathway.
Oncogene. 2009;28(4):492–9. doi:10.1038/onc.2008.403.
72. Kim JJ, Gill PS, Rotin L, van Eede M, Henkelman RM, Hui CC, et al.
Suppressor of fused controls mid-hindbrain patterning and cerebellar
morphogenesis via GLI3 repressor. J Neurosci. 2011;31(5):1825–36.
doi:10.1523/JNEUROSCI.2166-10.2011.
73. Min TH, Kriebel M, Hou S, Pera EM. The dual regulator Sufu integrates
Hedgehog and Wnt signals in the early Xenopus embryo. Dev Biol.
2011;358(1):262–76. doi:10.1016/j.ydbio.2011.07.035.
74. Brugieres L, Remenieras A, Pierron G, Varlet P, Forget S, Byrde V, et al. High
frequency of germline SUFU mutations in children with desmoplastic/
nodular medulloblastoma younger than 3 years of age. J Clin Oncol.
2012;30(17):2087–93. doi:10.1200/JCO.2011.38.7258.
75. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF. Post-transcriptional down-
regulation of Atoh1/Math1 by bone morphogenic proteins suppresses
medulloblastoma development. Genes Dev. 2008;22(6):722–7. doi:10.1101/
gad.1636408.
76. Cao Y, Wang C, Zhang X, Xing G, Lu K, Gu Y, et al. Selective small molecule
compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated
Smad1/5 degradation. Sci Rep. 2014;4:4965. doi:10.1038/srep04965.
Vriend et al. Molecular Brain  (2015) 8:64 Page 11 of 14
77. Lau AW, Fukushima H, Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases
and their roles in tumorigenesis. Front Biosci. 2012;17:2197–212.
78. Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, Jandke A, Muhammad B,
et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting
Notch, Jun, and DEK for degradation. J Exp Med. 2011;208(2):295–312.
doi:10.1084/jem.20100830.
79. Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin
ligase: mechanisms and opportunities. Cancer Cell. 2014;26(4):455–64.
doi:10.1016/j.ccell.2014.09.013.
80. Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev
Cancer. 2014;14(4):233–47. doi:10.1038/nrc3700.
81. Ren H, Koo J, Guan B, Yue P, Deng X, Chen M, et al. The E3 ubiquitin ligases
beta-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1
degradation induced by the Akt inhibitor API-1, resulting in apoptosis.
Mol Cancer. 2013;12:146. doi:10.1186/1476-4598-12-146.
82. Tsuchiya Y, Morita T, Kim M, Iemura S, Natsume T, Yamamoto M, et al. Dual
regulation of the transcriptional activity of Nrf1 by beta-TrCP- and Hrd1-
dependent degradation mechanisms. Mol Cell Biol. 2011;31(22):4500–12.
doi:10.1128/MCB.05663-11.
83. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B,
et al. Inactivation of hCDC4 can cause chromosomal instability. Nature.
2004;428(6978):77–81. doi:10.1038/nature02313.
84. Hede SM, Savov V, Weishaupt H, Sangfelt O, Swartling FJ. Oncoprotein
stabilization in brain tumors. Oncogene. 2014;33(39):4709–21. doi:10.1038/
onc.2013.445.
85. Gulino A, Di Marcotullio L, Canettieri G, De Smaele E, Screpanti I.
Hedgehog/Gli control by ubiquitination/acetylation interplay. Vitam Horm.
2012;88:211–27. doi:10.1016/B978-0-12-394622-5.00009-2.
86. Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle.
Curr Biol. 2004;14(18):R787–96. doi:10.1016/j.cub.2004.09.020.
87. Penas C, Govek EE, Fang Y, Ramachandran V, Daniel M, Wang W, et al.
Casein kinase 1delta is an APC/C(Cdh1) substrate that regulates cerebellar
granule cell neurogenesis. Cell Rep. 2015;11(2):249–60. doi:10.1016/
j.celrep.2015.03.016.
88. Fasanaro P, Capogrossi MC, Martelli F. Regulation of the endothelial cell cycle
by the ubiquitin-proteasome system. Cardiovasc Res. 2010;85(2):272–80.
doi:10.1093/cvr/cvp244.
89. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear
factor kappa-B signaling reduces growth in medulloblastoma in vivo.
BMC Cancer. 2011;11:136. doi:10.1186/1471-2407-11-136.
90. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of
medulloblastoma. Expert Rev Neurother. 2012;12(7):871–84. doi:10.1586/
ern.12.66.
91. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation
and cancer. Mol Cancer. 2013;12:86. doi:10.1186/1476-4598-12-86.
92. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, et al.
Bortezomib induces nuclear translocation of IkappaBalpha resulting in gene-
specific suppression of NF-kappaB–dependent transcription and induction
of apoptosis in CTCL. Mol Cancer Res. 2011;9(2):183–94. doi:10.1158/
1541-7786.MCR-10-0368.
93. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al.
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in
medulloblastoma. Science. 2009;326(5952):572–4. doi:10.1126/science.1179386.
94. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P,
et al. APC mutations in sporadic medulloblastomas. Am J Pathol.
2000;156(2):433–7. doi:10.1016/S0002-9440(10)64747-5.
95. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, et al.
Genome sequencing of pediatric medulloblastoma links catastrophic DNA
rearrangements with TP53 mutations. Cell. 2012;148(1–2):59–71. doi:10.1016/
j.cell.2011.12.013.
96. Saran A. Medulloblastoma: role of developmental pathways, DNA repair
signaling, and other players. Curr Mol Med. 2009;9(9):1046–57.
97. Lee Y, Miller HL, Jensen P, Hernan R, Connelly M, Wetmore C, et al. A
molecular fingerprint for medulloblastoma. Cancer Res. 2003;63(17):5428–37.
98. Frappart PO, Lee Y, Russell HR, Chalhoub N, Wang YD, Orii KE, et al.
Recurrent genomic alterations characterize medulloblastoma arising from
DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A.
2009;106(6):1880–5. doi:10.1073/pnas.0806882106.
99. Gillette TG, Yu S, Zhou Z, Waters R, Johnston SA, Reed SH. Distinct functions
of the ubiquitin-proteasome pathway influence nucleotide excision repair.
EMBO J. 2006;25(11):2529–38. doi:10.1038/sj.emboj.7601120.
100. Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, et al.
sTRAIL coupled to liposomes improves its pharmacokinetic profile and
overcomes neuroblastoma tumour resistance in combination with
Bortezomib. J Control Release. 2014;192:157–66. doi:10.1016/
j.jconrel.2014.07.009.
101. Yang F, Jove V, Chang S, Hedvat M, Liu L, Buettner R, et al. Bortezomib
induces apoptosis and growth suppression in human medulloblastoma
cells, associated with inhibition of AKT and NF-kB signaling, and synergizes
with an ERK inhibitor. Cancer Biol Ther. 2012;13(6):349–57. doi:10.4161/
cbt.19239.
102. Ohshima-Hosoyama S, Davare MA, Hosoyama T, Nelon LD, Keller C.
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in
medulloblastoma. J Neurooncol. 2011;105(3):475–83. doi:10.1007/s11060-
011-0619-0.
103. Taniguchi E, Cho MJ, Arenkiel BR, Hansen MS, Rivera OJ, McCleish AT, et al.
Bortezomib reverses a post-translational mechanism of tumorigenesis for
patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer.
2009;53(2):136–44. doi:10.1002/pbc.21968.
104. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade
(Bortezomib). Cancer Invest. 2004;22(2):304–11.
105. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, et al. Bortezomib induces
osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF
signaling. Blood. 2009;113(18):4319–30. doi:10.1182/blood-2008-08-174300.
106. Luchetti F, Canonico B, Bartolini D, Arcangeletti M, Ciffolilli S, Murdolo G, et
al. Melatonin regulates mesenchymal stem cell differentiation: a review.
J Pineal Res. 2014;56(4):382–97. doi:10.1111/jpi.12133.
107. Yu YL, Chou RH, Shyu WC, Hsieh SC, Wu CS, Chiang SY, et al. Smurf2-
mediated degradation of EZH2 enhances neuron differentiation and
improves functional recovery after ischaemic stroke. EMBO Mol Med.
2013;5(4):531–47. doi:10.1002/emmm.201201783.
108. Naujokat C, Saric T. Concise review: role and function of the ubiquitin-
proteasome system in mammalian stem and progenitor cells. Stem Cells.
2007;25(10):2408–18. doi:10.1634/stemcells.2007-0255.
109. Drexler HC. Activation of the cell death program by inhibition of
proteasome function. Proc Natl Acad Sci U S A. 1997;94(3):855–60.
110. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes
play an essential role in thymocyte apoptosis. EMBO J. 1996;15(15):3835–44.
111. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. Proteasome
involvement and accumulation of ubiquitinated proteins in cerebellar
granule neurons undergoing apoptosis. J Neurosci. 2000;20(2):589–99.
112. Schuller U, Schober F, Kretzschmar HA, Herms J. Bcl-2 expression inversely
correlates with tumour cell differentiation in medulloblastoma. Neuropathol
Appl Neurobiol. 2004;30(5):513–21. doi:10.1111/j.1365-2990.2004.00553.x.
113. Lossi L, Zagzag D, Greco MA, Merighi A. Apoptosis of undifferentiated
progenitors and granule cell precursors in the postnatal human cerebellar
cortex correlates with expression of BCL-2, ICE, and CPP32 proteins. J Comp
Neurol. 1998;399(3):359–72.
114. Muller Y, Rocchi E, Lazaro JB, Clos J. Thyroid hormone promotes BCL-2
expression and prevents apoptosis of early differentiating cerebellar granule
neurons. Int J Dev Neurosci. 1995;13(8):871–85.
115. Krajewska M, Mai JK, Zapata JM, Ashwell KW, Schendel SL, Reed JC, et al.
Dynamics of expression of apoptosis-regulatory proteins Bid, Bcl-2, Bcl-X,
Bax and Bak during development of murine nervous system. Cell Death
Differ. 2002;9(2):145–57. doi:10.1038/sj.cdd.4400934.
116. Tian H, Zhang B, Di J, Jiang G, Chen F, Li H, et al. Keap1: one stone kills
three birds Nrf2, IKKbeta and Bcl-2/Bcl-xL. Cancer Lett. 2012;325(1):26–34.
doi:10.1016/j.canlet.2012.06.007.
117. Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2
and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873–86.
doi:10.1074/jbc.M111.312694.
118. Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2-an update. Free Radic Biol
Med. 2014;66:36–44. doi:10.1016/j.freeradbiomed.2013.02.008.
119. Bobba A, Canu N, Atlante A, Petragallo V, Calissano P, Marra E. Proteasome
inhibitors prevent cytochrome c release during apoptosis but not in
excitotoxic death of cerebellar granule neurons. FEBS Lett.
2002;515(1–3):8–12.
120. Porcile C, Piccioli P, Stanzione S, Bajetto A, Bonavia R, Barbero S, et al.
Proteasome inhibitors induce cerebellar granule cell death: inhibition of
nuclear factor-kB activation. Ann N Y Acad Sci. 2002;973:402–13.
121. Butts BD, Hudson HR, Linseman DA, Le SS, Ryan KR, Bouchard RJ, et al.
Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via
Vriend et al. Molecular Brain  (2015) 8:64 Page 12 of 14
differential regulation of pro-survival and pro-apoptotic transcription factors.
Mol Cell Neurosci. 2005;30(2):279–89. doi:10.1016/j.mcn.2005.07.011.
122. Harada T, Harada C, Wang YL, Osaka H, Amanai K, Tanaka K, et al. Role of
ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by
ischemic retinal injury in vivo. Am J Pathol. 2004;164(1):59–64. doi:10.1016/
S0002-9440(10)63096-9.
123. Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human jurkat T
cells by pentagalloylglucose through inhibiting proteasome activity and
elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J Biol Chem.
2004;279(14):13496–505. doi:10.1074/jbc.M212390200.
124. Lin KI, Baraban JM, Ratan RR. Inhibition versus induction of apoptosis by
proteasome inhibitors depends on concentration. Cell Death Differ.
1998;5(7):577–83. doi:10.1038/sj.cdd.4400384.
125. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy.
J Cell Commun Signal. 2011;5(2):101–10. doi:10.1007/s12079-011-0121-7.
126. Koulich E, Nguyen T, Johnson K, Giardina C, D’Mello S. NF-kappaB is
involved in the survival of cerebellar granule neurons: association of
IkappaBbeta [correction of Ikappabeta] phosphorylation with cell survival.
J Neurochem. 2001;76(4):1188–98.
127. Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, et al.
The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation
and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol.
2008;10(6):643–53. doi:10.1038/ncb1727.
128. Alvarez-Rodriguez R, Barzi M, Berenguer J, Pons S. Bone morphogenetic
protein 2 opposes Shh-mediated proliferation in cerebellar granule cells
through a TIEG-1-based regulation of Nmyc. J Biol Chem.
2007;282(51):37170–80. doi:10.1074/jbc.M705414200.
129. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, et al.
The neuronal repressor REST/NRSF is an essential regulator in
medulloblastoma cells. Nat Med. 2000;6(7):826–31. doi:10.1038/77565.
130. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, et al.
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells
causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol.
2006;26(5):1666–78. doi:10.1128/MCB.26.5.1666-1678.2006.
131. Negrini S, Prada I, D’Alessandro R, Meldolesi J. REST: an oncogene or a
tumor suppressor? Trends Cell Biol. 2013;23(6):289–95. doi:10.1016/
j.tcb.2013.01.006.
132. Fuller GN, Su X, Price RE, Cohen ZR, Lang FF, Sawaya R, et al. Many human
medulloblastoma tumors overexpress repressor element-1 silencing
transcription (REST)/neuron-restrictive silencer factor, which can be
functionally countered by REST-VP16. Mol Cancer Ther. 2005;4(3):343–9.
doi:10.1158/1535-7163.MCT-04-0228.
133. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, et al.
SCFbeta-TRCP controls oncogenic transformation and neural differentiation
through REST degradation. Nature. 2008;452(7185):370–4. doi:10.1038/
nature06780.
134. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2
and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer.
2008;8(6):438–49. doi:10.1038/nrc2396.
135. Barisone GA, Yun JS, Diaz E. From cerebellar proliferation to tumorigenesis:
new insights into the role of Mad3. Cell Cycle. 2008;7(4):423–7.
136. McLean JR, Chaix D, Ohi MD, Gould KL. State of the APC/C: organization,
function, and structure. Crit Rev Biochem Mol Biol. 2011;46(2):118–36.
doi:10.3109/10409238.2010.541420.
137. Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo
T, et al. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis.
Nature. 2008;452(7185):365–9. doi:10.1038/nature06641.
138. Limon-Mortes MC, Mora-Santos M, Espina A, Pintor-Toro JA, Lopez-Roman
A, Tortolero M, et al. UV-induced degradation of securin is mediated by
SKP1-CUL1-beta TrCP E3 ubiquitin ligase. J Cell Sci. 2008;121(Pt 11):1825–31.
doi:10.1242/jcs.020552.
139. Satija YK, Bhardwaj A, Das S. A portrayal of E3 ubiquitin ligases and
deubiquitylases in cancer. Int J Cancer. 2013;133(12):2759–68. doi:10.1002/
ijc.28129.
140. Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, et al. SEL-10 is an inhibitor
of notch signaling that targets notch for ubiquitin-mediated protein
degradation. Mol Cell Biol. 2001;21(21):7403–15. doi:10.1128/MCB.21.21.7403-
7415.2001.
141. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular
domain is ubiquitinated and negatively regulated by the mammalian Sel-10
homolog. J Biol Chem. 2001;276(38):35847–53. doi:10.1074/jbc.M103992200.
142. Jandke A, Da Costa C, Sancho R, Nye E, Spencer-Dene B, Behrens A. The
F-box protein Fbw7 is required for cerebellar development. Dev Biol.
2011;358(1):201–12. doi:10.1016/j.ydbio.2011.07.030.
143. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E, et al. Functional
interaction between SEL-10, an F-box protein, and the nuclear form of
activated Notch1 receptor. J Biol Chem. 2001;276(37):34371–8. doi:10.1074/
jbc.M101343200.
144. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H,
et al. Phosphorylation-dependent degradation of c-Myc is mediated by the
F-box protein Fbw7. EMBO J. 2004;23(10):2116–25. doi:10.1038/
sj.emboj.7600217.
145. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7
tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-
dependent c-Myc protein degradation. Proc Natl Acad Sci U S A.
2004;101(24):9085–90. doi:10.1073/pnas.0402770101.
146. Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase
SCFFbw7 antagonizes apoptotic JNK signaling. Science.
2004;303(5662):1374–8. doi:10.1126/science.1092880.
147. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al.
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7
ubiquitin ligase. Science. 2001;294(5540):173–7. doi:10.1126/science.1065203.
148. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, et al. Phosphorylation
by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the
SCF(beta-TRCP) ubiquitin ligase. Cancer Cell. 2010;18(2):147–59. doi:10.1016/
j.ccr.2010.06.015.
149. Punga T, Bengoechea-Alonso MT, Ericsson J. Phosphorylation and
ubiquitination of the transcription factor sterol regulatory element-binding
protein-1 in response to DNA binding. J Biol Chem. 2006;281(35):25278–86.
doi:10.1074/jbc.M604983200.
150. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, et al.
SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator
by targeting it for ubiquitin-mediated proteolysis. Genes Dev.
2008;22(2):252–64. doi:10.1101/gad.1624208.
151. Biswas M, Phan D, Watanabe M, Chan JY. The Fbw7 tumor suppressor
regulates nuclear factor E2-related factor 1 transcription factor turnover
through proteasome-mediated proteolysis. J Biol Chem.
2011;286(45):39282–9. doi:10.1074/jbc.M111.253807.
152. Bengoechea-Alonso MT, Ericsson J. Tumor suppressor Fbxw7 regulates
TGFbeta signaling by targeting TGIF1 for degradation. Oncogene.
2010;29(38):5322–8. doi:10.1038/onc.2010.278.
153. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for
the treatment of prostate cancer. Cancer Res. 2006;66(10):4996–5002.
doi:10.1158/0008-5472.CAN-05-2796.
154. Kwon YW, Kim IJ, Wu D, Lu J, Stock Jr WA, Liu Y, et al. Pten regulates
Aurora-A and cooperates with Fbxw7 in modulating radiation-induced
tumor development. Mol Cancer Res. 2012;10(6):834–44. doi:10.1158/1541-
7786.MCR-12-0025.
155. Welcker M, Clurman BE. The SV40 large T antigen contains a decoy
phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol
Chem. 2005;280(9):7654–8. doi:10.1074/jbc.M413377200.
156. Luan Y, Wang P. FBW7-mediated ubiquitination and degradation of KLF5.
World J Biol Chem. 2014;5(2):216–23. doi:10.4331/wjbc.v5.i2.216.
157. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, et al. FBXW7
targets mTOR for degradation and cooperates with PTEN in tumor
suppression. Science. 2008;321(5895):1499–502. doi:10.1126/science.1162981.
158. Pan Y, Bai CB, Joyner AL, Wang B. Sonic hedgehog signaling regulates Gli2
transcriptional activity by suppressing its processing and degradation. Mol
Cell Biol. 2006;26(9):3365–77. doi:10.1128/MCB.26.9.3365-3377.2006.
159. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, Mukhtar H, et al.
Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin
ligase. J Biol Chem. 2006;281(28):19320–6. doi:10.1074/jbc.M513203200.
160. Tempe D, Casas M, Karaz S, Blanchet-Tournier MF, Concordet JP. Multisite
protein kinase A and glycogen synthase kinase 3beta phosphorylation leads
to Gli3 ubiquitination by SCFbetaTrCP. Mol Cell Biol. 2006;26(11):4316–26.
doi:10.1128/MCB.02183-05.
161. Wang B, Li Y. Evidence for the direct involvement of {beta}TrCP in Gli3
protein processing. Proc Natl Acad Sci U S A. 2006;103(1):33–8. doi:10.1073/
pnas.0509927103.
162. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target
for the ubiquitin-proteasome pathway. EMBO J. 1997;16(13):3797–804.
doi:10.1093/emboj/16.13.3797.
Vriend et al. Molecular Brain  (2015) 8:64 Page 13 of 14
163. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-TrCP E3
ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene.
2004;23(11):2028–36. doi:10.1038/sj.onc.1207389.
164. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z. HOS, a human homolog of
Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the
phosphorylation-dependent degradation of IkappaB and beta-catenin.
Oncogene. 1999;18(12):2039–46. doi:10.1038/sj.onc.1202760.
165. Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of IkappaBalpha
by the F-box protein Slimb/beta-TrCP. Genes Dev. 1999;13(3):284–94.
166. Strack P, Caligiuri M, Pelletier M, Boisclair M, Theodoras A, Beer-Romero P, et
al. SCF(beta-TRCP) and phosphorylation dependent ubiquitinationof I kappa
B alpha catalyzed by Ubc3 and Ubc4. Oncogene. 2000;19(31):3529–36.
doi:10.1038/sj.onc.1203647.
167. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello
NV, et al. Degradation of Cdc25A by beta-TrCP during S phase and in
response to DNA damage. Nature. 2003;426(6962):87–91. doi:10.1038/
nature02082.
168. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD.
Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6
domain, one of which can be modulated by GSK-3 activity. Oncogene.
2013;32(32):3765–81. doi:10.1038/onc.2012.388.
169. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, et al. A novel
human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects
CD4 to the ER degradation pathway through an F-box motif. Mol Cell.
1998;1(4):565–74.
170. Shirogane T, Jin J, Ang XL, Harper JW. SCFbeta-TRCP controls clock-
dependent transcription via casein kinase 1-dependent degradation of the
mammalian period-1 (Per1) protein. J Biol Chem. 2005;280(29):26863–72.
doi:10.1074/jbc.M502862200.
171. Reischl S, Vanselow K, Westermark PO, Thierfelder N, Maier B, Herzel H, et al.
Beta-TrCP1-mediated degradation of PERIOD2 is essential for circadian
dynamics. J Biol Rhythms. 2007;22(5):375–86. doi:10.1177/
0748730407303926.
172. Eide EJ, Woolf MF, Kang H, Woolf P, Hurst W, Camacho F, et al. Control of
mammalian circadian rhythm by CKIepsilon-regulated proteasome-
mediated PER2 degradation. Mol Cell Biol. 2005;25(7):2795–807. doi:10.1128/
MCB.25.7.2795-2807.2005.
173. Zhou BP, Hung MC. Wnt, hedgehog and snail: sister pathways that control
by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle.
2005;4(6):772–6.
174. Wang Z, Zhong J, Gao D, Inuzuka H, Liu P, Wei W. DEPTOR ubiquitination
and destruction by SCF(beta-TrCP). Am J Physiol Endocrinol Metab.
2012;303(2):E163–9. doi:10.1152/ajpendo.00105.2012.
175. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, et al. Degradation of Mcl-1 by
beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression
and chemosensitization. Mol Cell Biol. 2007;27(11):4006–17. doi:10.1128/
MCB.00620-06.
176. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-
mediated degradation of the CDK inhibitor p27. Nat Cell Biol.
1999;1(4):193–9.
177. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and
degradation is regulated by the SCF(Skp2) complex through
phosphorylated Thr187 in p27. Curr Biol. 1999;9(12):661–4.
178. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko
A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1
in S phase. J Biol Chem. 2003;278(28):25752–7. doi:10.1074/
jbc.M301774200.
179. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2
complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl
Acad Sci U S A. 1998;95(19):11324–9.
180. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-
protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1
degradation. Nat Cell Biol. 1999;1(1):14–9. doi:10.1038/8984.
181. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3
ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and
tumorigenesis. Cell. 2012;149(5):1098–111. doi:10.1016/j.cell.2012.02.065.
182. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, et al.
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated
degradation. Proc Natl Acad Sci U S A. 2005;102(5):1649–54. doi:10.1073/
pnas.0406789102.
183. Moro L, Arbini AA, Marra E, Greco M. Up-regulation of Skp2 after prostate
cancer cell adhesion to basement membranes results in BRCA2 degradation
and cell proliferation. J Biol Chem. 2006;281(31):22100–7. doi:10.1074/
jbc.M604636200.
184. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are
essential elements of the cyclin A-CDK2 S phase kinase. Cell.
1995;82(6):915–25.
185. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I,
Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of
cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J.
2000;19(9):2069–81. doi:10.1093/emboj/19.9.2069.
186. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type
ubiquitin ligases. Semin Cell Dev Biol. 2005;16(3):323–33. doi:10.1016/
j.semcdb.2005.02.010.
187. Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, Bagchi S. The
papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and
Skp2-containing E3 ligase. J Virol. 2004;78(10):5338–46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vriend et al. Molecular Brain  (2015) 8:64 Page 14 of 14
